All Type of News
MSIP to sponsor new drug development up to non-clinical study with KRW 500 billion within 10 years
The government has attracted the industry as planning to carry out a project to support new drug development up to the non-clinical study phase with KRW 500 billion within 10 years.
Deputy Director Nam-Gyu Cho at the...
What are the government’s plans for investment into new drug in 2018?
The government is planning to enlarge support for new drug development in the initial phase, reduce the support in the commercialization phase, like Phase 3 clinical trials, and promote investments into private compan...
MFDS’s goal to increase self-sufficiency of Korean vaccines to 50%
In order to protect the national health through prevention of infectious diseases and stay alerted against bioterrorism, the Ministry of Food and Drug Safety(MFDS) announced on the 27th that it will strengthen the con...
Can the rest of companies not indicted be relieved from the rebate case of the hospital located in Jeonju?
While the rebate case of the hospital ‘J’ located in Jeonju is about to be finished, the Ministry of Food and Drug Safety(MFDS) has appeared as an unexpected enemy.
According to the industry concerned, the prosecutio...
Busan Eastern DPO completed rebate & drug price investigations
As Busan Eastern District Prosecutor’s Office(DPO) announced a result of the investigation in which the office has conducted towards pharmaceutical companies, doctors and hospitals, a number of pharmaceutical companie...
No. of employees in pharma industry reaches close to 100 thousand
The number of employees working in the pharmaceutical industry has reached close to 100 thousand people.
In the circumstance where the domestic market and investment have been depressed, the entire industries in Kore...
MOHW’s administrative measures will gain momentum on ‘Novartis’ rebate case’
The Novartis’ rebate case, which has been paused for a moment, will be accelerated by the Ministry of Health and Welfare(MOHW) in administrative disposition.
According to the MOHW on the 27th, the ministry will annou...
Will water-leaking Korean Pharmaceutical Association Bldg. be discussed for reconstruction?
The issue of reconstructing Korean Pharmaceutical Association Bldg. has been raised again. The industry has shown interests if the issue will be voted by the members in favor of the reconstruction.
The members have a...
Kyowa Kakko Kirin signs license agreement of hyperphosphatemia treatment ‘Nephoxil’
Kyowa Hakko Kirin Korea(CEO Shigeaki Suzuki) announced a license agreement of the hyperphosphatemia treatment ‘Nephoxil’ with Taiwanese Panion & BF Biotech on the 20th of February.
Hyperphosphatemia is a symptom in w...
MOHW, “We are planning to extend health insurance benefits for immune-oncology agents”
Insurance benefits and indications for additional immune-oncology agents will be extended.
The Ministry of Health and Welfare(MOHW) announced the Liberty Korea Party Rep. Il-Jong Sung’s plan to extend application of ...
